Subscribe To

Price Alert Latest News Economic Calendar News

OVID / Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET in New York, New York. Read More

Demo Live Account See Partner Details

Content Topics

OVID

Therapeutics

Present

2023

Cantor

Fitzgerald

Global

Healthcare

Conference

Stock

Posted: Sep 20 2023, 07:30

Author Name: GlobeNewsWire

OVID News

By GlobeNewsWire
September 20, 2023

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that

By Zacks Investment Research
August 4, 2023

Ovid Therapeutics (OVID) Reports Q2 Loss, Lags Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to lo

By Seeking Alpha
June 13, 2023

Ovid Therapeutics: Bullish Outlook Strengthened By Positive 2-Year Open-Label Trial Results

Ovid Therapeutics' TAK-935 has a high potential for positive Phase 3 clinical trial results for both Dravet Syndrome (DS) and Lennox-Gastaut Syndrome

By Zacks Investment Research
May 5, 2023

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to lo

By Zacks Investment Research
April 12, 2023

Ovid Therapeutics (OVID) Upgraded to Buy: Here's What You Should Know

Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.